Navigation Links
Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation
Date:9/2/2009

WASHINGTON, Sept. 2 /PRNewswire-FirstCall/ -- Danaher Corporation (NYSE: DHR) today announced that it has signed a definitive agreement with MDS Inc. (TSX: MDS; NYSE: MDZ) to acquire the Analytical Technologies division of MDS, which includes a 50% ownership position in Applied Biosystems/MDS Sciex joint venture ("AB SCIEX"), a mass spectrometry business, and a 100% ownership position in the former Molecular Devices Corporation, a bioresearch and analytical instrumentation company. In a separate, but related transaction, Danaher also announced that it has signed a definitive agreement with Life Technologies Corporation (Nasdaq: LIFE) to acquire the remaining 50% ownership position in AB SCIEX. After completion of both transactions, Danaher will own outright AB SCIEX and Molecular Devices. The aggregate purchase price for the combined transactions is $1.1 billion, including debt assumed and net of cash acquired.

AB SCIEX is a leading designer and manufacturer of mass spectrometers, highly sensitive and sophisticated instruments used by researchers and clinicians to identify and quantify specific molecules in complex samples. AB SCIEX sells into the research, applied and clinical markets. Typical applications include proteomics research, drug development, food and environmental safety testing and diagnostics testing. Customers include academic and research institutions, pharmaceutical development labs primarily supporting clinical trials, testing and reference labs and hospitals. Molecular Devices supplies high-performance bio-analytical instrumentation systems and consumables that accelerate and improve research productivity and effectiveness in life science research and drug discovery.

The acquired businesses will operate within Danaher's Medical Technologies segment, joining Danaher's Leica, Radiometer, Sybron, and KaVo businesses, and will expand the segment's annual revenues by more than $650 million. The acquired businesses will increase Danaher's life sciences and diagnostics annual revenues to more than $2 billion. Danaher's Medical Technologies brands are some of the most highly recognized in each of their respective product segments.

Danaher's President and CEO, H. Lawrence Culp, Jr., said, "AB SCIEX is the market leader in mass spectrometry and its instruments address the needs of a broad scientific community involved in many applications including the research, applied and clinical markets. Additionally, Molecular Devices is known for high-quality, innovative products in the segments it serves. We are excited about the opportunity to acquire two leading brands in the life sciences instrumentation market, which will complement our existing Medical Technologies businesses and present an attractive value creation opportunity."

The transaction with MDS Inc. is subject to approval of the MDS shareholders. Both transactions are subject to regulatory approval and customary closing conditions, including the absence of material adverse change with respect to the acquired businesses. Danaher expects the transactions to close in the fourth quarter of 2009.

Danaher will host a conference call to discuss the transactions on September 2, 2009 at 8:30 AM ET. The U.S. dial-in number is 888-516-2435; the international dial-in number is 719-457-2637; with reference ID Code 8896948. A telephone replay will be available by dialing 888-203-1112 in the US; and 719-457-0820 internationally; with ID Code 8896948. The replay will be available through September 6, 2009. The conference call and replay will also be available via webcast in the Investor section of www.danaher.com.

About Danaher

Danaher (NYSE: DHR), based in Washington. D.C., is a diversified technology leader that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. Our portfolio of premier brands is among the most highly recognized in each of the markets we serve. Driven by strong core values and a foundation provided by the Danaher Business System, our 50,000 associates serve customers in more than 125 countries and generated $12.7 billion of revenue in 2008. For more information please visit our website: www.danaher.com.

Statements in this document that are not strictly historical, including statements regarding the proposed acquisition, the expected timetable for completing the transactions, future financial and operating results, benefits and synergies of the transactions, future opportunities for the combined company and any other statements about managements' future expectations, beliefs, goals, plans or prospects, may constitute forward looking statements. These are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements. These factors include, among other things: general economic conditions and conditions affecting the industries in which AB SCIEX and Molecular Devices operate; the uncertainty of regulatory approvals; the parties' ability to satisfy the closing conditions and consummate the transactions; Danaher's ability to successfully integrate AB SCIEX and Molecular Devices operations and employees with Danaher's existing business; and the ability to realize anticipated growth, synergies and cost savings. Additional information regarding factors that may cause actual results to differ materially from these forward-looking statements is available in Danaher's SEC filings, including Danaher's 2008 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended July 3, 2009. These forward-looking statements speak only as of the date of this release and Danaher does not assume any obligation to update any forward-looking statement.


'/>"/>
SOURCE Danaher Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Danaher to Present at Morgan Stanley Global Industrials Conference
2. Danaher Corporation Announces Retirement of Executive Vice President Philip W. Knisely
3. Danaher Announces Quarterly Dividend
4. Shareholders Challenge Danaher/Kerr to Phase Out Mercury Tooth Fillings
5. Danaher to Present at Barclays Capital Industrial Select Conference
6. Danaher CEO Comments on Outlook
7. Danaher to Present at Goldman Sachs Global Industrials Conference
8. Danaher Corporation Schedules First Quarter Conference Call
9. Danaher to Present at Citigroup Global Industrial Manufacturing Conference
10. Danaher Closes Subsequent Offering Period for Tektronix; Acquires Over 90% of TEK Shares
11. Mission Pharmacal Acquires Dr. Smiths Diaper Ointment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... (CDC), rising prescription opioid overdose deaths now claim the lives of 62 Americans ... civil case filings against drug manufacturers, distributors, pharmacies and prescribers by more than ...
(Date:4/24/2017)... ... , ... Rod Burkett, CEO of Gardant Management Solutions, was recently featured in ... the forefront of Gardant since it was founded in 1999. His drive and inquisitive ... more than 40 new senior living communities. With his leadership, Gardant has grown to ...
(Date:4/24/2017)... ... 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 and ... educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd said, ... patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, ...
(Date:4/24/2017)... NY (PRWEB) , ... April 24, 2017 , ... ... 72 countries clearly shows that over the last decade, student well-being has seriously ... all the boxes of formal education, join the Islamic State to turn the ...
(Date:4/24/2017)... ... ... “The Saint with Trin, and Omega Station”: a triple feature offering nonstop ... published author, Chris Jackson. Chris Jackson grew up in Abilene, Texas. He ... District teaching English. He is heavily involved in the youth group of his local ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Deutsche Bank ... Hotel in Boston, Massachusetts on ... 11:20 a.m. Eastern Time. A live webcast ... Investor Relations website at http://investor.zimmerbiomet.com .  The webcast ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
Breaking Medicine Technology: